Penumbra(PEN)
Focus: Penumbra is a public medical device company specializing in minimally-invasive vascular and surgical devices for acute stroke, pulmonary embolism, and intracranial hemorrhage. The company operates at ~$1.1B in FY2025 revenue with strong recent growth and profitability.
Profile data last refreshed 11h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
85+11 this month
Growing — net +11 jobs in 30d
43 jobs added vs 32 removed. Steady team buildout.
Should You Work at Penumbra?
AI assessmentBest suited for commercial, operational, and manufacturing professionals seeking growth in a profitable, acquisition-target medical device company; limited appeal for pure research scientists.
Why Work Here
- Strong revenue growth (30% YoY in FY2025) and return to profitability ($91M net income) signals financial stability and reinvestment capacity
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$1.1B
Pipeline & Clinical Trials
Penumbra System
Stroke, IschemicClinical Trials (1)
NCT04157270LOTUS: Global Acute Stroke Study Utilizing Penumbra System
N/AHelp build intelligence for Penumbra
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.